Article Text

Download PDFPDF

Treatment of Paget's disease of bone with single dose intravenous pamidronate.
  1. R A Watts,
  2. S J Skingle,
  3. M M Bhambhani,
  4. G Pountain,
  5. A J Crisp
  1. Department of Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom.


    OBJECTIVES--To assess the efficacy of a single intravenous infusion of pamidronate in Paget's disease of bone. METHODS--Fourteen patients with active Paget's disease (raised serum alkaline phosphatase, bone pain or neurological involvement) were treated with a single intravenous infusion of 105 mg pamidronate. Patients were assessed for biochemical and clinical improvement for up to two years following treatment. A further infusion was given following symptomatic relapse (pain at a known site of pagetic involvement). RESULTS--Serum alkaline phosphatase fell following treatment, with a nadir 5.9 months after treatment. Bone pain was improved in nine of 12 patients after six months. Retreatment of four patients resulted in a similar response. CONCLUSION--Single dose intravenous pamidronate (105 mg) is a convenient and effective treatment for Paget's disease.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.